Difference between revisions of "CT Angiography Biomarker Ctte"
m (→Meetings) |
m |
||
| Line 8: | Line 8: | ||
'''Recent Call Summaries:''' | '''Recent Call Summaries:''' | ||
| − | *[[Media: 2019 10 30 QIBA CT Angiography_SME_FINAL.pdf | October 30, 2019 (SME call)]] | + | *[[Media: 2019 10 30 QIBA CT Angiography_SME_FINAL-2.pdf | October 30, 2019 (SME call)]] |
*[[Media: 2019 10 07 QIBA CT Angiography_FINAL.pdf | October 7, 2019]] | *[[Media: 2019 10 07 QIBA CT Angiography_FINAL.pdf | October 7, 2019]] | ||
*[[Media: 2019 09 09 QIBA CT Angiography_FINAL.pdf | September 9, 2019]] | *[[Media: 2019 09 09 QIBA CT Angiography_FINAL.pdf | September 9, 2019]] | ||
Revision as of 21:47, 12 November 2019
Co-chairs: Andrew Buckler, MS; Luca Saba, MD; Uwe Joseph Schoepf, MD, FAHA, FSCBT-MR, FNASCI, FSCCT RSNA Staff Support: Julie Lisiecki
Meetings
Recent Call Summaries:
- October 30, 2019 (SME call)
- October 7, 2019
- September 9, 2019
- August 26, 2019
- August 12, 2019
- July 29, 2019
- Hiatus for public comment period (April - July)
- April 8, 2019
- March 11, 2019
- February 25, 2019
CT Angiography Call Summaries Archive
Project Snapshot - CT Angiography
The group intends to pursue writing quantitative profiles for both Coronary computed tomography angiography (CCTA) and CT angiography (CTA).
Excerpt from the biomarker committee submission form:
The QIBA Atherosclerosis Biomarkers Committee (ABC) is organized to document quantitative profiles for both Computed Tomography Angiography (CTA) and Coronary CTA (CCTA). The membership is composed of participants from multiple centers of excellence within North America and Europe utilizing different CTA vendors, acquisitions and scanner types, and analysis software vendors. Representatives from different manufacturers are included in the committee, who are interested in working closely with the committee in optimizing imaging biomarkers for scientific trials and clinical routine use. The Biomarker Committee develops technical performance standards to serve as atherosclerosis compositional biomarkers, engaging stakeholders from different societies, in addition to the RSNA, for example ASNR, SCCT, ACR, etc.
Profile Development
- QIBA Atherosclerosis Biomarkers Profile Draft | October 30, 2019
- QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet | October 30, 2019
- QIBA Atherosclerosis Biomarkers Profile Draft | September 9, 2019
- QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet | September 9, 2019
- QIBA Atherosclerosis Biomarkers Profile Draft | August 26, 2019
- QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet | August 26, 2019
- QIBA Atherosclerosis Biomarkers Profile Draft | August 12, 2019
- QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet | August 12, 2019
- QIBA Atherosclerosis Biomarkers Profile Draft | July 29, 2019
- QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet | July 29, 2019
- QIBA Atherosclerosis Biomarkers Profile Draft | February 26, 2019
- QIBA Atherosclerosis Biomarkers Profile Draft | February 11, 2019
- QIBA Atherosclerosis Biomarkers Profile Draft | January 31, 2019
- QIBA Atherosclerosis Biomarkers Profile Draft | January 14, 2019
- QIBA Atherosclerosis Biomarkers Profile Draft | December 17, 2018
Atherosclerosis Biomarkers Profile Draft Archive
Groundwork Projects
Reference Materials
- QIBA Biomarkers Selection Criteria Atherosclerosis Biomarker Committee (ABC) {Mr. Buckler} March 27, 2018 (PDF)